Press Releases

Date Title and Summary Additional Formats
Toggle Summary Retrophin Announces U.S. FDA Acceptance of NDA Filing for the New Formulation of Thiola® (tiopronin) in the Treatment of Cystinuria
PDUFA date set for June 30, 2019 SAN DIEGO , Nov. 12, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that the U.S. Food and Drug Administration ( FDA ) has accepted for review the New Drug Application (NDA) for a new formulation of Thiola (tiopronin) in the treatment of
View HTML
Toggle Summary Retrophin to Present at the Jefferies 2018 London Healthcare Conference
SAN DIEGO , Nov. 07, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Stephen Aselage , chief executive officer, will present at the Jefferies 2018 London Healthcare Conference in London, UK on Wednesday, November 14, 2018 at 4:40 p.m. GMT ( 11:40 a.m. ET ).
View HTML
Toggle Summary Retrophin Reports Third Quarter 2018 Financial Results
Pivotal programs enrolling towards first data readout in 2019 Phase 2 study of CNSA-001 in PKU underway; top-line results expected in first half 2019 Completed offering of $276 million convertible senior notes due 2025 SAN DIEGO, Calif. , Nov. 01, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc.
View HTML
Toggle Summary Retrophin Reports Positive Long-Term Data from Open-Label Extension of Phase 2 DUET Study of Sparsentan for the Treatment of Focal Segmental Glomerulosclerosis
Increasing achievement of FSGS partial remission of proteinuria and stable eGFR observed out to 84 weeks in open-label extension Findings presented at ASN Kidney Week 2018 SAN DIEGO , Oct. 26, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced new positive data from the ongoing
View HTML
Toggle Summary Retrophin Announces Publication of Phase 2 DUET Study of Sparsentan for the Treatment of Focal Segmental Glomerulosclerosis in the Journal of the American Society of Nephrology
DUET publication highlighted during Best of ASN Journals session at ASN Kidney Week 2018 SAN DIEGO , Oct. 25, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that the Journal of the American Society of Nephrology (JASN) has published online (doi: 10.1681/ASN.2018010091 ) the
View HTML
Toggle Summary Retrophin to Report Third Quarter 2018 Financial Results
SAN DIEGO , Oct. 18, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced it will report third quarter 2018 financial results on Thursday, November 1, 2018 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial
View HTML
Toggle Summary Retrophin to Present Long-Term Data from Phase 2 DUET Study of Sparsentan in FSGS at ASN Kidney Week 2018
SAN DIEGO , Oct. 05, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that it will present new data examining the long-term effects of sparsentan in focal segmental glomerulosclerosis (FSGS), at the American Society of Nephrology (ASN) Kidney Week 2018.
View HTML
Toggle Summary Retrophin to Highlight Fosmetpantotenate Program for PKAN at Upcoming Medical Congresses
SAN DIEGO , Oct. 03, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that presentations highlighting the design of the ongoing pivotal Phase 3 FORT Study of fosmetpantotenate for the treatment of pantothenate kinase-associated neurodegeneration (PKAN), the patient and
View HTML
Toggle Summary Retrophin Announces Upcoming Presentations at the 15th International Symposium on IgA Nephropathy
SAN DIEGO , Sept. 27, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced two upcoming presentations related to its development program for sparsentan in the treatment of IgA nephropathy (IgAN), a rare kidney disorder often resulting in end-stage renal disease, during the 15 th
View HTML
Toggle Summary Retrophin to Present at Upcoming Investor Conferences
SAN DIEGO , Sept. 17, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that the Company’s management team will present at the following upcoming investor conferences in October: Cantor Global Healthcare Conference Date: Monday, October 1, 2018 Time: 4:40 p.m.
View HTML